Company Reports

Recent Updates

All Reports

Stock Analyst Note

Illumina reported third-quarter results on Oct. 29 that included 4.7% organic revenue growth outside of China (versus its 4.5% prior guidance) and 7% adjusted earnings per share growth to $1.44 (versus its $1.33-$1.38 prior guidance). Management also raised its 2026 guidance.
Company Report

Illumina continues to focus on transforming human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related consumables to help researchers and clinicians identify and understand genetic variations. The scale of these projects can be wide, such as population genomic initiatives being pursued in many countries, or narrow, such as noninvasive prenatal screening. We believe Illumina will continue to benefit from the rapidly expanding applications of genomic sequencing tools through its own innovation and select acquisitions.
Stock Analyst Note

Illumina's first-quarter results included 4% organic sales growth, 13% adjusted operating profit growth, and 19% adjusted earnings per share growth to $1.15, about 10 cents above FactSet consensus. Management raised its 2026 outlook on these results, including a $0.10 higher 2026 EPS outlook range.
Stock Analyst Note

Life science stocks have been under pressure since late 2022, but with profits expected to rebound in the high single digits in 2026 on average and potentially accelerate even further in 2027-30 due to upcoming catalysts, we see growing momentum in the industry’s profit growth trajectory.
Stock Analyst Note

At an investor conference on Jan. 13, Illumina presented preliminary 2025 financial results of flat revenue growth in constant currency, or above its prior goal of a 0.5% to 1.5% decline, and midteens earnings per share growth to $4.76-4.79, or above its prior outlook of $4.65-$4.75.
Company Report

Illumina continues to focus on transforming human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related consumables to help researchers and clinicians identify and understand genetic variations. The scale of these projects can be wide, such as population genomic initiatives being pursued in many countries, or narrow, such as noninvasive prenatal screening. We believe Illumina will continue to benefit from the rapidly expanding applications of genomic sequencing tools through its own innovation and select acquisitions.
Company Report

Illumina continues to focus on transforming human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related consumables to help researchers and clinicians identify and understand genetic variations. The scale of these projects can be wide, such as population genomic initiatives being pursued in many countries, or narrow, such as noninvasive prenatal screening. We believe Illumina will continue to benefit from the rapidly expanding applications of genomic sequencing tools through its own innovation and select acquisitions.
Company Report

Illumina continues to focus on transforming human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related consumables to help researchers and clinicians identify and understand genetic variations. The scale of these projects can be wide, such as population genomic initiatives being pursued in many countries, or narrow, such as noninvasive prenatal screening. We believe Illumina will continue to benefit from the rapidly expanding applications of genomic sequencing tools through its own innovation and select acquisitions.
Company Report

Illumina continues to focus on transforming human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related consumables to help researchers and clinicians identify and understand genetic variations. The scale of these projects can be wide, such as population genomic initiatives being pursued in many countries, or narrow, such as noninvasive prenatal screening. We believe Illumina will continue to benefit from the rapidly expanding applications of genomic sequencing tools through its own innovation and select acquisitions.
Stock Analyst Note

Narrow-moat Illumina announced third-quarter results that looked strong on the bottom line, and management increased its adjusted earnings per share guidance moderately for 2024. After tinkering with our near-term assumptions and keeping our longer-term view roughly intact, our $144 fair value estimate still looks appropriate. Shares appear fairly valued to us.
Company Report

Illumina continues to focus on transforming human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related consumables to help researchers and clinicians identify and understand genetic variations. The scale of these projects can be wide, such as population genomic initiatives being pursued in many countries, or narrow, such as noninvasive prenatal screening. We believe Illumina will continue to benefit from the rapidly expanding applications of genomic sequencing tools through its own innovation and select acquisitions.
Stock Analyst Note

Narrow-moat Illumina's new management team gave long-term goals at its investor day that were weaker than we previously expected. As a result, we are reducing our fair value estimate to $144 per share from $188 previously, on a weaker assumptions for the sequencing business, which was informed by management's disclosures at the investor day.

Sponsor Center